TARS - Wutah pendapatan taunan sajrone rolas wulan kepungkur Tarsus Pharmaceuticals

Logo grafis tarsusrx.com (TARS)

The annual growth rate of trailing twelve months (LTM) revenue on the GURU.Markets base chart shows that the metric for Tarsus Pharmaceuticals (TARS) is 86.00. Patent protection and FDA approval create a powerful regulatory barrier for competitors. Tarsus Pharmaceuticals (TARS) possesses pricing power due to the lack of comparable drugs for blepharitis. The integration of this unique therapy into demodicosis treatment protocols establishes a new, unrivaled standard in ophthalmology.

Wutah dodolan YoY sajrone rolas wulan kepungkur Tarsus Corp (TARS): kanggo periode 11.02.2024 - 18.11.2026

Tarsus Pharmaceuticals - rincian analitis lan metrik utama (TARS)

- rega saiki lan proyeksi nilai saham:
Ringkesan analitik perusahaan:TARS (Tarsus Corp)
Produk mawa merek Tarsus Corp

This metric reflects revenue dynamics over the last twelve months, capturing the consensus estimate of sales growth rates compared to the same period last year. For Tarsus Pharmaceuticals (TARS), this 12-month YoY sales trend confirms the monetization of a unique drug with inelastic demand. The lack of alternatives provides the company with pricing power and stable market expansion. However, it is critical for investors to correlate this growth with the cost side to mitigate risks in the event of a demand slowdown.